newsroom
$HIMS · the investor who called palantir at $7 is now buying peptides
now playing · $HIMS
$HIMS···bullish· high· posantonio linares
Linares long Hims as winner-take-all longevity data network
Hims' vertically integrated infrastructure and D2C distribution (4-5M customers) position it to build the dominant longitudinal biomarker network, where AI correlates proteomic da…
$DUOL···bullish· high· posantonio linares
Duolingo held as education singularity scalar for AI tutor
Duolingo will deliver the 'superhuman AI tutor' in education, becoming the dominant network that uses proprietary learning data to bootload the most intelligent AI for personalize…
$PLTR···bullish· high· posantonio linares
Palantir held after early conviction call at $7
Palantir represents a singularity scalar in government/enterprise data networks, held since early conviction at $7 as part of a portfolio where one winner validates the thesis.
$TSLA···bullish· medium· posantonio linares
Tesla held as part of concentrated singularity scalar portfolio
Tesla is a core holding in a portfolio betting on winner-take-all data networks that will deploy superhuman AI in their domains (autonomy, energy, robotics).
$SPOT···bullish· medium· posantonio linares
Spotify held as part of concentrated singularity scalar portfolio
Spotify is one of seven core holdings in a portfolio betting on winner-take-all networks that leverage proprietary data to dominate their verticals via AI.
$AMD···bullish· medium· posantonio linares
AMD held as part of concentrated singularity scalar portfolio
AMD is a core holding in a concentrated portfolio betting on companies that will become dominant AI-powered networks in their respective industries.
$IBRX···bullish· low· posantonio linares
ImmunityBio added as micro-investment in gene/cell therapy
Small position in ImmunityBio as exposure to gene editing and cell therapy, which Linares views as the 'hardware level' beyond peptides for curative outcomes driven by data and AI.
$WHOOPbullish· mediumantonio linares
Whoop positioned to build proprietary biomarker labs from wearable data
Whoop's high-level biomarker data (HRV, resting heart rate, strain) from 2.5M customers creates a natural funnel to invest in vertically integrated labs for longitudinal health da…
Oura Ring seen as contender but lacks investor familiarity
Oura has similar D2C distribution and biomarker capabilities as Whoop but Linares is neither an investor nor customer, limiting conviction in its execution on the longevity data n…